We assessed the rates of vertebral fracture in patients with postmenopausal osteoporosis. Forty-five patients were not treated (91 person-years of observation); 59 were treated conventionally, with calcium (alone or combined with estrogen) or vitamin D or both (218 years); and 61 were treated with sodium fluoride combined with conventional therapy (251 years). The fracture rate (per thousand person-years) was 834 in untreated patients, 419 in those given calcium with or without vitamin D, 304 in those given fluoride and calcium with or without vitamin D, 181 in those given estrogen and calcium with or without vitamin D, and 53 in those given fluoride, estrogen, and calcium with or without vitamin D. It was reduced in all treatment groups (P less than 0.001 for calcium and P less than 1 x 10(-6) for other combinations); fluoride (one years of treatment) and estrogen (but not vitamin D) independently reduced the rate from that observed with calcium alone (P less than 0.001). The combination of calcium fluoride, and estrogen was more effective than any other combination (P less than 0.001). These results provide grounds for optimism about the efficacy of combinations of available agents with sodium fluoride for fracture in postmenopausal osteoporosis.
This article has been cited by other articles:
Prince, R. L., Devine, A., Dhaliwal, S. S., Dick, I. M.
(2006). Effects of Calcium Supplementation on Clinical Fracture and Bone Structure: Results of a 5-Year, Double-blind, Placebo-Controlled Trial in Elderly Women.. Arch Intern Med
166: 869-875
[Abstract][Full Text]
Hodsman, A. B., Hanley, D. A., Ettinger, M. P., Bolognese, M. A., Fox, J., Metcalfe, A. J., Lindsay, R.
(2003). Efficacy and Safety of Human Parathyroid Hormone-(1-84) in Increasing Bone Mineral Density in Postmenopausal Osteoporosis. J. Clin. Endocrinol. Metab.
88: 5212-5220
[Abstract][Full Text]
Chen, Z., Pettinger, M. B., Ritenbaugh, C., LaCroix, A. Z., Robbins, J., Caan, B. J., Barad, D. H., Hakim, I. A.
(2003). Habitual Tea Consumption and Risk of Osteoporosis: A Prospective Study in the Women's Health Initiative Observational Cohort. Am J Epidemiol
158: 772-781
[Abstract][Full Text]
Moghadasian, M. H., Frohlich, J. J.
(2001). Statins and bones. CMAJ
164: 803-805
[Full Text]
Cummings, S. R., Bauer, D. C.
(2000). Do Statins Prevent Both Cardiovascular Disease and Fracture?. JAMA
283: 3255-3257
[Full Text]
Alexandersen, P., Riis, B. J., Christiansen, C.
(1999). Monofluorophosphate Combined with Hormone Replacement Therapy Induces a Synergistic Effect on Bone Mass by Dissociating Bone Formation and Resorption in Postmenopausal Women: A Randomized Study. J. Clin. Endocrinol. Metab.
84: 3013-3020
[Abstract][Full Text]
Perry, H. M. III
(1999). The Endocrinology of Aging. Clin. Chem.
45: 1369-1376
[Abstract][Full Text]
Hulley, P. A., Gordon, F., Hough, F. S.
(1998). Inhibition of Mitogen-Activated Protein Kinase Activity and Proliferation of an Early Osteoblast Cell Line (MBA 15.4) by Dexamethasone: Role of Protein Phosphatases. Endocrinology
139: 2423-2431
[Abstract][Full Text]
Lems, W. F, Jacobs, J. W G, Bijlsma, J. W J, van Veen, G. J M, Houben, H. H M L, Haanen, H. C M, Gerrits, M. I, van Rijn, H. J M
(1997). Is addition of sodium fluoride to cyclical etidronate beneficial in the treatment of corticosteroid induced osteoporosis?. Ann Rheum Dis
56: 357-363
[Abstract][Full Text]
Wu, L.-W., Yoon, H. K., Baylink, D. J., Graves, L. M., Lau, K.-H. W.
(1997). Fluoride at Mitogenic Doses Induces a Sustained Activation of p44mapk, but Not p42mapk, in Human TE85 Osteosarcoma Cells. J. Clin. Endocrinol. Metab.
82: 1126-1135
[Abstract][Full Text]
Windeler, J., Lange, S.
(1995). Events per person year--a dubious concept. BMJ
310: 454-456
[Full Text]
Previous
